Association of p53Pro72Arg (rs1042522) and MDM2309 (rs2279744) polymorphisms with risk for cervical intraepthelial lesions and cervical cancer development in Macedonian women
-
Published:2016
Issue:2
Volume:62
Page:49-58
-
ISSN:1857-8969
-
Container-title:Macedonian Pharmaceutical Bulletin
-
language:en
-
Short-container-title:Maced. Pharm. Bull.
Author:
Duvlis Sotirija,Hiljadnikova Bajro Marija,Plaseska Karanfilska Dijana
Abstract
High risk Human Papillomavirus (HPV) is an important etiological factor in initiation of squamous intraepithelial lesions (SIL), but not enough for malignant progression to cervical cancer (CCa). Single nucleotide polymorphisms (SNPs): rs1042522 within the codon 72 of p53 and rs2279744 within MDM2 promoter gene are plausible factors for development of SIL or CCa conferring increased attenuation of p53 pathway. We investigated the association of these SNPs with the HPV positive SIL and CCa among women from the Republic of Macedonia. Using a multiplex PCR SNaPShot analysis we genotyped rs1042522 and rs2279744 in 131 HPV positive women with SIL or CCa and 110 HPV and cytologicaly negative controls subject. No significant difference in either genotype or allelic frequencies for rs1042522 and rs2279744 between cases and control was found. The stratification of patients on the basis of the lesion grade revealed
lower frequency of CC genotype and C allele of rs1042522 in HSIL and CCa compared to LSIL [GG vs CC; p=0.001, OR=0.4; CG vs CC; p=0.04, OR=0.03 and CG+ GG vs CC; p=0.004, OR=0.2]. Additionally TT genotype and T allele of MDM2 309 showed significantly lower frequency in HSIL and CCa group then in LSIL [G vs T p=0.02, OR=0.52; GG vs TT; p=0.04, OR=0.29; ТТ vs ТG+GG; p=0.007, OR=0.34].The Arg variant of rs1042522 and T allele/TT genotype of rs2279744 are associated with progression to LSIL to HSIL or CCa and may be used as prediction markers in CCa management, but the clinical relevant warrants further validation in large and well-designed
studies
Publisher
Macedonian Pharmaceutical Association
Reference34 articles.
1. Amaral, C.M., Cetkovska K., Gurgel, A.P., Cardoso, M.V., Chagas, B.S., Paiva Junior, S.S., de Lima Rde, C., SilvaNeto, J.C., Silva, L.A., Muniz, M.T., Balbino, V.Q., Freitas, A.C., 2014. MDM2 polymorphism associated with the development of cervical lesions in women infected with Human papillomavirus and using of oral contraceptives. Infect. Agent. Cancer 9, 24. DOI: 10.1186/1750-9378-9-24. 2. Beckman, G., Birgander, R., Sjalander A., Saha, N., Holmberg, P.A., Kivela, A., Beckman, L., 1994. Is p53 polymorphism maintained by natural selection? Hum. Hered. 44(5), 266- 270. 3. Birgander, R., Sjalander, A., Zhou, Z., Fan, C., Beckman, L., Beckman, G., 1996. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum. Hered. 46(1), 49-54. 4. Bjornslett, M., Knappskog, S., Lonning, P.E., Dorum, A., 2012. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC Cancer 12, 454. DOI: 10.1186/1471-2407-12-454. 5. Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., Onel, K., Yip, L., Hwang, S.J., Strong, L.C., Lozano, G., Levine, A.J., 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119(5), 591-602. DOI: 10.1016/j.cell.2004.11.022.
|
|